bullish
M3: Covid Related Trials and Yen Depreciation Support Earnings Beat
163 Views03 Nov 2022 13:36
m3's 2Q earnings beat consensus driven by Covid related projects and weaker yen which helped overseas biz post strong results. Medical Platform is a cash cow whose growth prospects becoming stagnant
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
- Chindata Takeover: China Merchants Enters as Government Interest in Data Centers Increase15 Nov 2022
- Freee: Earnings Beat and Losses Widen as Freee Focuses on Mid-To-Long Term Plan15 Nov 2022
- Recruit 2Q: Outlook for HR Tech Business Becomes Challenging15 Nov 2022
- M3: Covid Related Trials and Yen Depreciation Support Earnings Beat03 Nov 2022
- M3: Revenue and OP Beat Consensus but Don’t Rush to Make an Entry28 Jul 2022
- M3: Valuation to Further Drop as Earnings Momentum Slows Down16 Jun 2022
- M3: Share Price Heading into a Correction and Further 20-25% Downside Likely22 Dec 2021
x